Edition:
United Kingdom

Pluristem Therapeutics Inc (PSTI.OQ)

PSTI.OQ on NASDAQ Stock Exchange Capital Market

0.85USD
14 Dec 2018
Change (% chg)

$-0.03 (-3.41%)
Prev Close
$0.88
Open
$0.87
Day's High
$0.92
Day's Low
$0.85
Volume
52,694
Avg. Vol
45,505
52-wk High
$1.63
52-wk Low
$0.80

Latest Key Developments (Source: Significant Developments)

Pluristem Therapeutics Enters Into Cell Thawing Device License Agreement With Chart Industries, Inc.
Tuesday, 4 Dec 2018 

Pluristem Therapeutics Inc ::PLURISTEM THERAPEUTICS ENTERS INTO CELL THAWING DEVICE LICENSE AGREEMENT WITH CHART INDUSTRIES, INC..PLURISTEM THERAPEUTICS INC - CHART OBTAINS EXCLUSIVE RIGHTS TO MANUFACTURE AND MARKET THAWING DEVICE IN ALL TERRITORIES WORLDWIDE, EXCLUDING CHINA.PLURISTEM THERAPEUTICS INC - CO WILL BE RECEIVING ROYALTIES FROM SALES OF PRODUCT AND SUPPLY OF AN AGREED NUMBER OF DEVICES.  Full Article

Pluristem Therapeutics Reports Fiscal 2019 First Quarter Results
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Pluristem Therapeutics Inc ::PLURISTEM THERAPEUTICS REPORTS FISCAL 2019 FIRST QUARTER RESULTS AND PROVIDES CORPORATE UPDATE.PLURISTEM THERAPEUTICS INC - AS OF SEPTEMBER 30, 2018, HAD APPROXIMATELY $30 MILLION IN RESOURCES.  Full Article

Pluristem Reports Fiscal 2018 Fourth Quarter Results And Provides Corporate Update
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - Pluristem Therapeutics Inc ::PLURISTEM REPORTS FISCAL 2018 FOURTH QUARTER RESULTS AND PROVIDES CORPORATE UPDATE.PLURISTEM THERAPEUTICS - AS OF JUNE 30, 2018, PLURISTEM HAD $30.6 MILLION IN CASH AND CASH EQUIVALENTS, BANK DEPOSITS AND RESTRICTED DEPOSITS.  Full Article

Pluristem Therapeutics Announces FDA Orphan Drug Designation For PLX Cell Therapy
Tuesday, 25 Sep 2018 

Sept 25 (Reuters) - Pluristem Therapeutics Inc ::PLURISTEM THERAPEUTICS ANNOUNCES FDA ORPHAN DRUG DESIGNATION FOR PLX CELL THERAPY FOR THE TREATMENT OF GRAFT FAILURE AND INCOMPLETE RECOVERY FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION.PLURISTEM THERAPEUTICS INC - IN TRIAL, PRIMARY ENDPOINT IS SAFETY.  Full Article

Pluristem Initiates Two Pivotal Phase III Studies In Israel
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - Pluristem Therapeutics Inc ::PLURISTEM INITIATES TWO PIVOTAL PHASE III STUDIES IN ISRAEL.PLURISTEM THERAPEUTICS - BOTH TRIALS ACCEPTED TO ACCELERATED APPROVAL PATHWAYS.  Full Article

Pluristem Signs Collaboration Agreement With Thermo Fisher Scientific
Monday, 9 Jul 2018 

July 9 (Reuters) - Pluristem Therapeutics Inc ::PLURISTEM SIGNS COLLABORATION AGREEMENT WITH THERMO FISHER SCIENTIFIC.PLURISTEM THERAPEUTICS - ENTERED STRATEGIC COLLABORATION WITH THERMO FISHER SCIENTIFIC TO ADVANCE KNOWLEDGE OF CELL THERAPY INDUSTRIALIZATION.  Full Article

FDA Clears Pluristem’s Expanded Access Program To Initiate Treatments Of Critical Limb Ischemia
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Pluristem Therapeutics Inc ::PLURISTEM THERAPEUTICS - U.S. ‍FDA CLEARED CO'S EXPANDED ACCESS PROGRAM FOR USE OF PLX-PAD CELL TREATMENT IN PATIENTS WITH CRITICAL LIMB ISCHEMIA​.FDA CLEARS PLURISTEM’S EXPANDED ACCESS PROGRAM TO INITIATE TREATMENTS OF CRITICAL LIMB ISCHEMIA OUTSIDE OF ONGOING PHASE III STUDY.  Full Article

Pluristem enters agreement with Tel Aviv Sourasky Medical Center to conduct phase i/ii trial in steroid-refractory chronic GvHD
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Pluristem Therapeutics Inc :Pluristem enters into agreement with Tel Aviv Sourasky Medical Center to conduct phase i/ii trial in steroid-refractory chronic GvHD.  Full Article

PLURISTEM PRICES PUBLIC OFFERING OF COMMON STOCK ON THE TEL AVIV STOCK EXCHANGE
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Pluristem Therapeutics Inc ::PLURISTEM ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK ON THE TEL AVIV STOCK EXCHANGE.PLURISTEM THERAPEUTICS INC - ‍PRICING OF PUBLIC OFFERING OF 9 MILLION SHARES ON TEL AVIV STOCK EXCHANGE AT PRICE OF $1.67 (NIS 5.90) PER SHARE​.  Full Article

Pluristem extends trial for treatment of insufficient hematopoietic recovery
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Pluristem Therapeutics Inc :Following approval of israel’s ministry of health, Pluristem extends its trial of plx-r18 to treat insufficient Hematopoietic recovery after bone marrow transplant and opens clinical centers in Israel.Pluristem therapeutics inc - ‍Israeli clinical sites will join an ongoing u.s. Phase I trial​.  Full Article